Data generated from genome-wide DNA methylation profiling studies along with mechanistic work on the dysregulation of DNA methylation of key regulatory pathways (such as the imprinted DLK1-MEG3 locus in T2D), is likely to inspire the development of novel therapeutic approaches for augmenting beta cell function and mass. The gene discussed is DLK1; the disease is type 2 diabetes mellitus.